UGT2B7 C802T 和 CYP3A4*1G 多态性对接受奥施康定的癌症患者疼痛缓解的影响。
The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin.
机构信息
Department of Oncology, Xiangyang Center Hospital, Affiliated Hospital of Hubei University of Arts and Science, Jingzhou Street 39, Xiangyang, 441021, China.
Department of Neurosurgery, Xiangyang Center Hospital, Affiliated Hospital of Hubei University of Arts and Science, Jingzhou Street 39, Xiangyang, 441021, China.
出版信息
Support Care Cancer. 2018 Aug;26(8):2763-2767. doi: 10.1007/s00520-018-4130-4. Epub 2018 Mar 3.
BACKGROUND
Single nucleotide polymorphisms (SNPs) in UGT2B7 C802T and CYP3A4*1G impact drug metabolism. This study aimed to investigate the impact of these SNPs on the efficacy of oxycontin for pain relief in cancer patients.
METHODS
A total of 57 Han Chinese cancer patients (age range 20-70 years) who received oxycontin to ease pain for the first time were enrolled and divided into two groups (refractory group and remission group) according to pain relief. Peripheral blood samples were collected from each patient for sequencing analysis. The genotype and allele frequency between the two groups were analyzed using the chi-square test.
RESULTS
The T allele frequency of UGT2B7 C802T was 25% among all participants, but was higher (32%) in the refractory group (P = 0.047). The variant allele frequency of CYP3A4*1G was 27% and did not differ between the refractory group and remission group.
CONCLUSION
The palliative effect of oxycontin is better in patients with UGT2B7 802CC than in those with 802TT. CYP3A4*1G SNP is unlikely to affect pain relief efficacy of oxycontin.
背景
UGT2B7 C802T 和 CYP3A4*1G 的单核苷酸多态性（SNPs）影响药物代谢。本研究旨在探讨这些 SNPs 对羟考酮缓解癌症患者疼痛疗效的影响。
方法
共纳入 57 例首次接受羟考酮缓解疼痛的汉族癌症患者（年龄 20-70 岁），根据疼痛缓解情况将患者分为两组（难治组和缓解组）。采集每位患者的外周血样进行测序分析。采用卡方检验分析两组间基因型和等位基因频率。
结果
所有参与者中 UGT2B7 C802T 的 T 等位基因频率为 25%，但在难治组中较高（32%）（P=0.047）。CYP3A4*1G 的变异等位基因频率为 27%，在难治组和缓解组之间无差异。
结论
与 UGT2B7 802TT 相比，802CC 患者的羟考酮姑息治疗效果更好。CYP3A4*1G SNP 不太可能影响羟考酮的镇痛疗效。
Zotero 插件